Patents Assigned to NANJING LEADS BIOLABS CO., LTD
  • Antibodies binding TNFR2 and uses thereof
    Patent number: 11912777
    Abstract: The present invention relates to a novel antibody and antibody fragment that specifically binds to TNFR2 and to a composition comprising said antibody or antibody fragment. In addition, the present invention relates to a nucleic acid encoding the antibody or an antibody fragment thereof and a host cell comprising the same, and to a related use thereof. Besides, the present invention relates to the use of the antibody and antibody fragment for treatment and diagnosis.
    Type: Grant
    Filed: December 9, 2022
    Date of Patent: February 27, 2024
    Assignee: Nanjing Leads Biolabs Co., Ltd.
    Inventors: Xiaoqiang Kang, Shoupeng Lai, Xiao Huang, Huan Lin, Yujia Dang
  • RECOMBINANT PROTEIN TARGETING PD-1 AND TGFBETA
    Publication number: 20240025967
    Abstract: A recombinant fusion protein comprising 1) TGF?R2, or a fragment thereof, capable of binding to TGF?, and 2) an antibody, or an antigen-binding fragment thereof, that binds to PD-1. Also disclosed are a polynucleotide encoding the recombinant fusion protein, an expression vector containing the polynucleotide, a method for producing the recombinant protein and a method for treating a disease caused by over expression of TGF? and/or PD-1 using the recombinant protein.
    Type: Application
    Filed: September 22, 2023
    Publication date: January 25, 2024
    Applicant: Nanjing Leads Biolabs Co., Ltd.
    Inventors: Xiaoqiang Kang, Xiao Huang
  • Antibody binding TIM-3 and use thereof
    Patent number: 11807683
    Abstract: The present invention provides an isolated monoclonal antibody that specifically binds human TIM-3. The present invention further provides a pharmaceutical composition comprising the antibody, as well as uses thereof.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: November 7, 2023
    Assignee: Nanjing Leads Biolabs Co., Ltd.
    Inventors: Xiaoqiang Kang, Shoupeng Lai, Xiao Huang
  • Recombinant protein targeting PD-1 and TGFß
    Patent number: 11802145
    Abstract: A recombinant fusion protein comprising 1) TGF?R2, or a fragment thereof, capable of binding to TGF?, and 2) an antibody, or an antigen-binding fragment thereof, that binds to PD-1. Also disclosed are a polynucleotide encoding the recombinant fusion protein, an expression vector containing the polynucleotide, a method for producing the recombinant protein and a method for treating a disease caused by over expression of TGF? and/or PD-1 using the recombinant protein.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: October 31, 2023
    Assignee: Nanjing Leads Biolabs Co., Ltd.
    Inventors: Xiaoqiang Kang, Xiao Huang
  • Antibodies Binding TNFR2 and Uses Thereof
    Publication number: 20230212302
    Abstract: The present invention relates to a novel antibody and antibody fragment that specifically binds to TNFR2 and to a composition comprising said antibody or antibody fragment. In addition, the present invention relates to a nucleic acid encoding the antibody or an antibody fragment thereof and a host cell comprising the same, and to a related use thereof. Besides, the present invention relates to the use of the antibody and antibody fragment for treatment and diagnosis.
    Type: Application
    Filed: December 9, 2022
    Publication date: July 6, 2023
    Applicant: Nanjing Leads Biolabs Co., Ltd.
    Inventors: Xiaoqiang Kang, Shoupeng Lai, Xiao Huang, Huan Lin, Yujia Dang
  • ANTIBODIES BINDING 4-1BB AND USES THEREOF
    Publication number: 20230192862
    Abstract: Disclosed is an isolated monoclonal antibody that specifically binds human 4-1BB, or the antigen-binding portion thereof. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present disclosure further provides a bispecific molecule, and a pharmaceutical composition comprising the antibody or the bispecific molecule, as well as a treatment method using an anti-4-1BB antibody of the disclosure.
    Type: Application
    Filed: October 7, 2022
    Publication date: June 22, 2023
    Applicant: Nanjing Leads Biolabs Co., Ltd.
    Inventors: Xiaoqiang Kang, Xiao Huang, Jianming Sun
  • Antibodies binding 4-1BB and uses thereof
    Patent number: 11466086
    Abstract: Disclosed is an isolated monoclonal antibody that specifically binds human 4-1BB, or the antigen-binding portion thereof. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present disclosure further provides a bispecific molecule, and a pharmaceutical composition comprising the antibody or the bispecific molecule, as well as a treatment method using an anti-4-1BB antibody of the disclosure.
    Type: Grant
    Filed: September 30, 2020
    Date of Patent: October 11, 2022
    Assignee: Nanjing Leads Biolabs Co., Ltd.
    Inventors: Xiaoqiang Kang, Xiao Huang, Jianming Sun
  • Antibody binding PD-1 and use thereof
    Patent number: 11136394
    Abstract: The present invention provides an isolated monoclonal antibody that specifically binds human PD-1. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule and a pharmaceutical composition comprising the antibody, as well as a diagnostic and treatment method using an anti-PD-1 antibody of the invention.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: October 5, 2021
    Assignee: Nanjing Leads Biolabs Co., Ltd.
    Inventors: Xiaoqiang Kang, Shoupeng Lai, Xiao Huang
  • RECOMBINANT PROTEIN TARGETING PD-1 AND TGFβ
    Publication number: 20210115142
    Abstract: A recombinant fusion protein comprising 1) TGF?R2, or a fragment thereof, capable of binding to TGF?, and 2) an antibody, or an antigen-binding fragment thereof, that binds to PD-1. Also disclosed are a polynucleotide encoding the recombinant fusion protein, an expression vector containing the polynucleotide, a method for producing the recombinant protein and a method for treating a disease caused by over expression of TGF? and/or PD-1 using the recombinant protein.
    Type: Application
    Filed: October 20, 2020
    Publication date: April 22, 2021
    Applicant: Nanjing Leads Biolabs Co., Ltd.
    Inventors: Xiaoqiang Kang, Xiao Huang
  • ANTIBODIES BINDING 4-1BB AND USES THEREOF
    Publication number: 20210107982
    Abstract: Disclosed is an isolated monoclonal antibody that specifically binds human 4-1BB, or the antigen-binding portion thereof. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present disclosure further provides a bispecific molecule, and a pharmaceutical composition comprising the antibody or the bispecific molecule, as well as a treatment method using an anti-4-1BB antibody of the disclosure.
    Type: Application
    Filed: September 30, 2020
    Publication date: April 15, 2021
    Applicant: Nanjing Leads Biolabs Co., Ltd.
    Inventors: Xiaoqiang Kang, Xiao Huang, Jianming Sun
  • Antibodies binding LAG-3 and uses thereof
    Patent number: 10844121
    Abstract: The present invention provides an isolated monoclonal antibody that specifically binds LAG-3. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule and a pharmaceutical composition comprising the antibody, as well as a diagnostic and treatment method using an anti-LAG-3 antibody of the invention.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: November 24, 2020
    Assignee: NANJING LEADS BIOLABS CO., LTD
    Inventors: Xiaoqiang Kang, Shoupeng Lai, Xiao Huang, Lijun Zhou